258 related articles for article (PubMed ID: 16036093)
1. Combination/sequential therapy in osteoporosis.
Lecart MP; Bruyere O; Reginster JY
Curr Osteoporos Rep; 2004 Dec; 2(4):123-30. PubMed ID: 16036093
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of parathyroid hormone.
Cosman F; Lindsay R
Curr Osteoporos Rep; 2004 Mar; 2(1):5-11. PubMed ID: 16036076
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents.
Wimalawansa SJ
J Clin Densitom; 2000; 3(2):187-201. PubMed ID: 10871912
[TBL] [Abstract][Full Text] [Related]
4. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
5. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.
Cosman F
Curr Osteoporos Rep; 2014 Dec; 12(4):385-95. PubMed ID: 25341476
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
7. ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).
Adis International Ltd
Drugs R D; 2003; 4(4):231-5. PubMed ID: 12848587
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
Shen L; Xie X; Su Y; Luo C; Zhang C; Zeng B
PLoS One; 2011; 6(10):e26267. PubMed ID: 22022584
[TBL] [Abstract][Full Text] [Related]
9. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
11. [Anabolic treatment for osteoporosis: PTH treatment].
Kaji H; Sugimoto T
Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
[TBL] [Abstract][Full Text] [Related]
12. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
13. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.
Adami S
Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041
[TBL] [Abstract][Full Text] [Related]
14. A review of combination regimens for osteoporosis--prevention and treatment.
Miller E; Kalin MF
Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
[TBL] [Abstract][Full Text] [Related]
15. The potential of parathyroid hormone as a therapy for osteoporosis.
Rubin MR; Bilezikian JP
Int J Fertil Womens Med; 2002; 47(3):103-15. PubMed ID: 12081255
[TBL] [Abstract][Full Text] [Related]
16. Oral antiresorptive therapy.
Pande I; Hosking DJ
Curr Osteoporos Rep; 2004 Dec; 2(4):116-22. PubMed ID: 16036092
[TBL] [Abstract][Full Text] [Related]
17. Postmenopausal osteoporosis.
Selby P
Curr Osteoporos Rep; 2004 Sep; 2(3):101-6. PubMed ID: 16036090
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
Fogelman I; Fordham JN; Fraser WD; Spector TD; Christiansen C; Morris SA; Fox J
Calcif Tissue Int; 2008 Aug; 83(2):85-92. PubMed ID: 18626566
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
